

Ulcerative Colitis and Crohn's Disease Committee meeting

Date: 28/02/2018

Location: Manchester

Minutes: Approved

Committee members present:	
Tessa Lewis (Chair)	(Present for items 1 – 6)
Rachel Cooney	(Present for items 1 – 5)
Sarah Cripps	(Present for items 1 – 6)
Jenny Epstein	(Present for items 1 – 4)
Bruce George	(Present for items 1 – 6)
Richard Harris	(Present for items 1 – 6)
Sophia Joseph	(Present for items 1 – 6)
Themba Mudege	(Present for items 1 – 6)
Thomas Mytton	(Present for items 1 – 6)
Robert Palmer	(Present for items 1 – 6)
Janindra Warusavitarne	(Present for items 1 – 6)

In attendance:		
Omnia Abdulrazeg	Technical Analyst	(Present for items 1 – 6)
Chris Carmona	Senior Technical Analyst	(Present for items 1 – 6)
Bernadette Li	Technical Analyst – Health Economics	(Present for items 1 – 6)
Rui Martins (observing)	Technical Analyst	(Present for items 1 – 6)
Anneka Patel	Project Manager	(Present for items 1 – 6)
Gabriel Rogers	Technical Advisor - Health Economics	(Present for items 1 – 6)
Susan Spiers	Associate Director	(Present for items 1 – 6)

Apologies:	
Charmian Banks	Committee member
Sarah Cripps	Committee member
Joan Gavin	Committee member
Leslie Hayes	NICE - Business Analyst
Caroline Keir	NICE - Guideline Commissioning Manager

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the third meeting on Ulcerative Colitis and Crohn's Disease. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: the clinical and cost-effectiveness of corticosteroids, aminosalicylates, immunomodulators (methotrexate, mycophenolate and tacrolimus) for the induction of remission compared to themselves (different preparations and doses), each other, combinations of preparations (oral and topical) and placebo.

Introductions

The Chair welcomed all to the third meeting.

1. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest the matter under discussion is the clinical and cost-effectiveness of corticosteroids, aminosalicylates, immunomodulators (methotrexate, mycophenolate and tacrolimus) for the induction of remission compared to themselves (different preparations and doses), each other, combinations of preparations (oral and topical) and placebo.

The Chair asked everyone to verbally declare any interests.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

2. Presentations – Ulcerative Colitis clinical evidence results

The Chair introduced Omnia Abdulrazeg, technical analyst, who presented the network meta-analysis for the clinical review.

The Chair thanked Omnia for their presentation.

3. Presentations - Ulcerative Colitis health economic results

The Chair introduced Bernadette Li, health economist, who discussed with the Committee the details of the economic analysis.

The Chair thanked Bernadette for their presentation.

4. Committee discussion – drafting recommendations

The committee were given the opportunity to ask questions about the evidence presented, and discussed draft recommendations. The committee made a total of ten draft recommendations and two research recommendations.

5. AOB

There were no items for AOB.

6. Summary and next steps

The Chair advised the date of the next meeting (see below) and Anneka Patel explained that the next three meetings will focus on Crohn's disease.

The Chair thanked the committee for their attendance and closed the meeting.

Date of next meeting: 17/04/2018

Location of next meeting: Manchester